分化型甲状腺癌合并远处转移多次^(131)I治疗的时间间隔选择及疗效评价的研究进展  

The Research Progress on the Interval Selection and Efficacy Evaluation Between Multiple ^(131)I Treatments for Differentiated Thyroid Cancer with Distant Metastasis

作　　者：石磊[1] 张慧敏 谢谦[1] 胡德胜[1] SHI Lei;ZHANG Huimin;XIE Qian;HU Desheng(Department of Nuclear Medicine,The Fifth People’s Hospital of Chengdu,Chengdu 631110,China)

机构地区：[1]成都市第五人民医院核医学科,四川成都611130

出　　处：《标记免疫分析与临床》2022年第6期1071-1074,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：分化型甲状腺癌(DTC)合并远处转移术后可联合^(131)I治疗,患者血清甲状腺球蛋白(Tg)水平下降,转移灶影像学改善,病灶持续摄碘,则可重复甚至多次^(131)I治疗。重复治疗时间间隔多是根据指南建议或经验性选择3~12月,尚无统一的复治时机和指征推荐,宽泛的时间间隔选择势必会导致临床实践的不规范和随意性,且已有文献证实短期内接受多次大剂量^(131)I治疗发生不良反应的风险显著增加。因此,笔者整理相关文献,综述了多次^(131)I治疗的时间间隔选择和疗效评价的研究进展,以期为临床诊治实践提供帮助。Differentiated thyroid cancer with extensive distant metastases can be treated with RAI(radioiodine)therapy.If decreased serum thyroglobulin(Tg)levels,improved imaging performances,and RAI-avid metastases are observed,patients can further receive multiple RAI therapies.However,the time interval of repeated treatments,ranging from 3 months to 12 months,is mainly decided empirically or based on the current guideline,without clear standards of time windows and indications,which can inevitably induce irregularity and subjectivity of clinical practices.It is reported that multiple high-dose RAI therapies during a short period were associated with numerous adverse reactions of multiple organs.Therefore,Collating the relevant literature,the authors reviewed the latest developments regarding determination of appropriate time interval of multiple RAI therapies,in order to provide suggestions for theronostic practice of DTC patients with distant metastases.

关 键 词：分化型甲状腺癌 重复治疗 时间间隔 ^(131)I治疗 

分 类 号：R736.1[医药卫生—肿瘤]